Products
Posnafusp Biosimilar Fab Fusion Protein (Transferrin Receptor 1) for Research
Cat No.: GMP-Bios-INN-1341
Anti-TFRC/CD71 therapeutic antibody (Pre-made Posnafusp biosimilar,Fab Fusion Protein) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Posnafusp (development code JR-441) is a humanized Fab fusion protein in which an antibody fragment targeting human transferrin receptor 1 (TFRC/CD71) is fused to the enzyme N-sulphoglucosamine sulphohydrolase (SGSH) as a BBB-penetrating enzyme replacement therapy. It is developed by JCR Pharmaceuticals for mucopolysaccharidosis type III (Sanfilippo syndrome). It is in Phase I/II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1341-1mg | 1mg | 3090 |
| GMP-Bios-INN-1341-10mg | 10mg | |
| GMP-Bios-INN-1341-100mg | 100mg | |
| GMP-Bios-INN-1341-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Posnafusp biosimilar, Fab Fusion Protein targeting TFRC/CD71: Recombinant therapeutic protein targeting CD71/TFRC/Transferrin receptor protein 1/TR |
| INN Name | Posnafusp |
| Target | TFRC/CD71 |
| Format | Fab Fusion Protein |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | JCR Pharmaceuticals |
| Conditions Approved | na |
| Conditions Active | Mucopolysaccharidosis III |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
